Key facts
- It has raised $22.0M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Lapam Capital, Tsing Stone Asset Management, Founder Hesheng Investment, Tsinghua Innovation Ventures, Chang Development — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Super Vision
- ·The full record, as it builds
Funding rounds
No funding rounds for Super Vision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Super Vision
Developer of medical devices designed for the treatment of eye diseases. The company offers a combination of functional electrical nerve stimulation technology and eye muscles based on the experimental results of Liberson's functional electrical nerve stimulation technology, thereby aiming to produce medical devices that can eliminate nystagmus and improve vision.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Website
- supervisiontech.cn/
- Ownership
- Privately Held (backing)
Super Vision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Super Vision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Super Vision in its N-PORT filings yet. We sweep new filings monthly.